drugset / Trial / NCT00328718

Pediatric ADVAIR DISKUS Versus Oral Montelukast Chewable Tablets

NCT00328718

Phase 3 Completed 526 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being conducted to demonstrate the superior clinical effectiveness of Salmeterol/Fluticasone Propionate compared to montelukast in the management of persistent asthma in children aged 6-14 years, and to assess the effect of each treatment \[Salmeterol/Fluticasone Propionate (50/100 mcg) and montelukast (5 mg)\] on lung function, asthma control, Health Outcomes including the child's quality of life as measured by Paediatric Asthma Quality of Life Questionnaire (PAQLQ) and the caregiver's quality of life as measured by Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ) at selected centers where a valid translation is available.

Timeline

Start
2005-10
Primary completion
2007-04
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 100 ug Inhaled
Subject Montelukast Other / unclassified 5 mg Oral
Subject Salmeterol Other / unclassified 50 ug Inhaled

Indications